search
Back to results

A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.

Primary Purpose

Advanced Malignant Solid Tumor

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
IAE0972
Sponsored by
SUNHO(China)BioPharmaceutical CO., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Malignant Solid Tumor focused on measuring EGFR, IL10, Advanced Malignant Solid Tumor

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 1. Ability to provide informed consent and documentation of informed consent prior to initiation of any study-related tests or procedures that are not part of standard of care for the patient's disease. Patients must also be willing and able to comply with study procedures, including the acquisition of specified research specimens.

    2. Male or female, of any race, aged between 18 years and 80 years; 3. With histologically or cytologically confirmed locally advanced or metastatic solid malignant tumors, either refractory to standard therapy or for which no effective therapy was available.

    4. Measurable disease as determined by RECIST version 1.1 and documented by computed tomography (CT) and/or magnetic resonance imaging (MRI).

    5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Life expectancy ≥ 12 weeks. 7. Resolution of all chemotherapy or radiation-related toxicities to ≤ Grade 1 (with exception of ≤ Grade 2 alopecia, stable sensory neuropathy, or stable electrolyte disturbances that are managed by supplementation).

    8. Acceptable laboratory parameters as follows:

    1. Platelet count (PLT) ≥ 90 × 109/L without transfusion within 2 weeks prior to the initiation of investigational product.
    2. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L in the absence of any growth factor support within 2 weeks prior to the initiation of investigational product.
    3. International normalized ratio of prothrombin time (INR) ≤ 1.5 × upper limit of normal (ULN), activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
    4. Hemoglobin (HGB) ≥ 90 g/L.
    5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN; for patients with hepatic metastases, ALT and AST ≤ 5.0 × ULN.
    6. Total bilirubin ≤ 1.5 × ULN, except patients with Gilbert's syndrome, who may enroll if the conjugated bilirubin is within normal limits.
    7. Serum creatinine < 1.5 × ULN, or estimated creatinine clearance ≥ 60 mL/min as measured or calculated using the Cockcroft-Gault formula.

      9. Female patients of childbearing potential (not surgically sterilized and between menarche and 1- year postmenopause) must have a negative serum or urine pregnancy test performed within 7 days prior to the initiation of investigational product administration. Further, female patients of childbearing potential must agree to use highly effective contraceptive measures (include hormonal contraceptives, intrauterine device or system, vasectomy, or tubal ligation) from the time of consent through 3 months after discontinuation of investigational product administration.

      10. Male patients with partners of childbearing potential must use barrier contraception. In addition, male patients should also have their partners use another method of contraception from the time of consent through 3 months after discontinuation of investigational product administration.

      Exclusion Criteria:

  • 1. Known hypersensitivity (≥ Grade 3) to recombinant proteins or any excipient contained in the drug or vehicle formulation for IAE0972.

    2. History of another malignancy or a concurrent malignancy. Exceptions include patients who have been disease free for two years, or successfully treated for non-melanoma skin cancer, localized prostate cancer (Gleason Score < 6) or carcinoma in situ, for example cervical cancer in situ, are eligible.

    3. Treatment with any systemic anti-neoplastic therapy, radiation therapy or investigational therapy within 4 weeks prior to the initiation of investigational product administration, with the following exceptions:

    1. Nitrosourea or mitomycin C should be within 6 weeks prior to the initiation of investigational product administration.
    2. Oral fluoropyrimidines and small molecule targeted drugs should be within 2 weeks or 5 half-lives (whichever is later) prior to the initiation of investigational product administration.

      4. History of trauma or major surgery within 4 weeks prior to the initiation of investigational product administration.

      5. Treatment with corticosteroids (prednisone ≥ 10 mg per day or equivalent) or other immune suppressive drugs within the 14 days prior to the initiation of investigational product administration. Steroids for topical, ophthalmic, inhaled or nasal administration are allowed.

      6. Treatment with immunomodulatory agents, including but not limited to thymosin, interleukin-2 and interferon within 14 days prior to the initiation of investigational product administration.

      7. Vaccination with any live virus vaccine within 4 weeks prior to the initiation of investigational product administration.

      8. History of prior allogeneic bone marrow, stem-cell or solid organ transplantation.

      9. Active brain or leptomeningeal metastases. Patients with brain metastases are eligible if these have been treated and MRI or CT shows no evidence of progression for at least 8 weeks after treatment completion and within 4 weeks prior to the initiation of investigational product. Patients are not eligible if they required high doses of systemic corticosteroids that could result in immunosuppression (>10 mg/day prednisone equivalents) for at least 2 weeks prior to the initiation of investigational product.

      10. Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of investigational product. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than one week prior to the initiation of investigational product.

      11. Known history of hepatitis B or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction (PCR).

      12. Known positive testing for human immunodeficiency virus (HIV) or history of acquired immune deficiency syndrome (AIDS).

      13. Clinically significant pulmonary compromise, including a requirement for supplemental oxygen use to maintain adequate oxygenation.

      14. History of clinically significant cardiovascular disease including but not limited to:

    1. Myocardial infarction or unstable angina within the 6 months prior to the initiation of investigational product.
    2. Stroke or transient ischemic attack within 6 months prior to the initiation of investigational product.
    3. Clinically significant cardiac arrhythmias, or a QTc prolongation to > 470 millisecond (ms) corrected by Fridericia's method based on a 12-lead electrocardiogram (ECG) in screening.
    4. Uncontrolled hypertension: systolic blood pressure (SBP) >180 mmHg, diastolic blood pressure (DBP) >100 mmHg.
    5. Congestive heart failure (New York Heart Association [NYHA] class III-IV).
    6. Pericarditis or clinically significant pericardial effusion.
    7. Myocarditis.
    8. Left ventricle ejection fraction (LVEF) < 50% by echocardiogram. 15. Any history of known or suspected autoimmune disease with the specific exceptions of vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic treatment (within the past 2 years), and patients with a history of autoimmune disease that are now clinically stable with replacement therapy and by laboratory testing.

      16. History of ≥ grade 3 immune-related adverse events (irAE) or Grade 2 immune-associated myocarditis accompanied with immunotherapy.

      17. Clinically uncontrolled effusion in the third space. 18. Known alcohol or drug dependence. 19. Dementia or altered mental status that would preclude understanding and rendering of informed consent.

      20. The female patient who is pregnant or breastfeeding, or expecting to conceive, AND the male patient who is expecting to father children within the projected duration of the trial, starting with the screening visit through 90 days after the last dose of trial treatment.

      21. Any issue that in the opinion of the investigator, would contraindicate the patient's participation in the study or confound the results of the study.

Sites / Locations

  • Affilated Cancer Hospital of Shandong First Medical University
  • Shanghai East HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Phase Ia - Dose escalation(Acceleration Stage)

Phase Ia - Dose escalation(3+3 Stage)

Phase Ib - Dose extension

Phase IIa - Clinical Exploratory Stage

Arm Description

Phase Ia is an open, non-random, single-arm dose escalation design.

Phase Ia is an open, non-random, single-arm dose escalation design.

Phase Ib is an open, non-random, single-arm, multi-center research design.

The Phase IIa is planned to be divided into three indication groups, all of which are open, non-randomized, single-arm research design.

Outcomes

Primary Outcome Measures

To evaluate the safety and tolerability of IAE0972 in Phase I
MTD/R2PD ,Incidence and frequency of DTL; AE,SAE occurrence and frequency (according to NCI CTCAE 5.0)
Objective response rate (ORR) in Phase IIa
To explore the effectiveness of IAE0972.

Secondary Outcome Measures

Pharmacokinetic (PK) Cmax
PK parameters Cmax following single dose
Pharmacokinetic (PK) Css,max
PK parameters Css,max following multiple doses
Pharmacokinetic (PK) Css,min
PK parameters Css,min following multiple doses
Pharmacokinetic (PK) Css,av
PK parameters Css,av following multiple doses
Pharmacokinetic (PK) AUCss
PK parameters AUCss following multiple doses
Pharmacokinetic (PK) CLss
PK parameters CLss following multiple doses
Pharmacokinetic (PK) Vss
PK parameters Vss following multiple doses
Pharmacokinetic (PK) R
PK parameters R following multiple doses
Pharmacokinetic (PK) DF
PK parameters DF following multiple doses
Pharmacokinetic (PK) Cmin
PK parameters Cmin following single dose
Pharmacokinetic (PK) Tmax
PK parameters Tmax following single dose
Pharmacokinetic (PK) AUC0-t
PK parameters AUC0-t following single dose
Pharmacokinetic (PK) AUC0-∞
PK parameters AUC0-∞ following single dose
Pharmacokinetic (PK) CL
PK parameters CL following single dose
Pharmacokinetic (PK) Vd
PK parameters Vd following single dose
Pharmacokinetic (PK) t1/2
PK parameters t1/2 following single dose
Pharmacokinetic (PK) λz
PK parameters λz following single dose
Objective response rate (ORR) (Phase I )
To explore the preliminary effectiveness of IAE0972.
Overall survival (OS) (Phase I )
To explore the preliminary effectiveness of IAE0972.
Disease control rate (DCR) (Phase I )
To explore the preliminary effectiveness of IAE0972.
To evaluate the Immunogenicity of IAE0972 in patients with advanced malignant solid tumors (Phase I )
The frequency of anti-drug antibodies(ADA) against IAE0972
Progression-free survival(PFS) in Phase II
To explore the effectiveness of IAE0972.
Overall survival (OS)in Phase II
To explore the effectiveness of IAE0972.
Disease control rate (DCR) in Phase II
To explore the effectiveness of IAE0972.
Immunogenicity of IAE0972 (Phase II )
The frequency of anti-drug antibodies(ADA) against IAE0972
Incidence of adverse event (AEs) and SAEs (Phase II)
To investigate the safety characteristics

Full Information

First Posted
May 19, 2022
Last Updated
July 18, 2023
Sponsor
SUNHO(China)BioPharmaceutical CO., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05396339
Brief Title
A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.
Official Title
A Phase I/IIa Clinical Trial to Evaluate the Safety,Tolerability,Pharmacokinetics and Preliminary Effectiveness of IAE0972 in Patients With Advanced Malignant Solid Tumors.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 24, 2022 (Actual)
Primary Completion Date
May 30, 2024 (Anticipated)
Study Completion Date
November 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
SUNHO(China)BioPharmaceutical CO., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a Phase I/IIa Clinical Trial to Evaluate the Safety,Tolerability,Pharmacokinetics and Preliminary Effectiveness of IAE0972 in Patients With Advanced Malignant Solid Tumors.
Detailed Description
The study includes three phases: dose escalation (Phase Ia), dose extension (Phase Ib), and clinical exploration (Phase IIa).First, the Phase Ia dose escalation will be carried out. After finishing the Phase 1a dose escalation, the Phase Ib dose extension study can be carried out in the MTD dose which is obtained from Phase 1a . After Phase Ia &1b are completed and RP2D is obtained, Phase IIa clinical exploratory research can be carried out.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Malignant Solid Tumor
Keywords
EGFR, IL10, Advanced Malignant Solid Tumor

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Phase Ia - Dose escalation(Acceleration Stage)
Arm Type
Experimental
Arm Description
Phase Ia is an open, non-random, single-arm dose escalation design.
Arm Title
Phase Ia - Dose escalation(3+3 Stage)
Arm Type
Experimental
Arm Description
Phase Ia is an open, non-random, single-arm dose escalation design.
Arm Title
Phase Ib - Dose extension
Arm Type
Experimental
Arm Description
Phase Ib is an open, non-random, single-arm, multi-center research design.
Arm Title
Phase IIa - Clinical Exploratory Stage
Arm Type
Experimental
Arm Description
The Phase IIa is planned to be divided into three indication groups, all of which are open, non-randomized, single-arm research design.
Intervention Type
Drug
Intervention Name(s)
IAE0972
Intervention Description
IAE0972 is an investigational product
Primary Outcome Measure Information:
Title
To evaluate the safety and tolerability of IAE0972 in Phase I
Description
MTD/R2PD ,Incidence and frequency of DTL; AE,SAE occurrence and frequency (according to NCI CTCAE 5.0)
Time Frame
28 days after last medication, an average of 1 year
Title
Objective response rate (ORR) in Phase IIa
Description
To explore the effectiveness of IAE0972.
Time Frame
Baeline until disease progression, assessed up to 36 months
Secondary Outcome Measure Information:
Title
Pharmacokinetic (PK) Cmax
Description
PK parameters Cmax following single dose
Time Frame
after single dose , an average of 1 year
Title
Pharmacokinetic (PK) Css,max
Description
PK parameters Css,max following multiple doses
Time Frame
after multiple doses , an average of 1 year
Title
Pharmacokinetic (PK) Css,min
Description
PK parameters Css,min following multiple doses
Time Frame
after multiple doses , an average of 1 year
Title
Pharmacokinetic (PK) Css,av
Description
PK parameters Css,av following multiple doses
Time Frame
after multiple doses , an average of 1 year
Title
Pharmacokinetic (PK) AUCss
Description
PK parameters AUCss following multiple doses
Time Frame
after multiple doses , an average of 1 year
Title
Pharmacokinetic (PK) CLss
Description
PK parameters CLss following multiple doses
Time Frame
after multiple doses , an average of 1 year
Title
Pharmacokinetic (PK) Vss
Description
PK parameters Vss following multiple doses
Time Frame
after multiple doses , an average of 1 year
Title
Pharmacokinetic (PK) R
Description
PK parameters R following multiple doses
Time Frame
after multiple doses , an average of 1 year
Title
Pharmacokinetic (PK) DF
Description
PK parameters DF following multiple doses
Time Frame
after multiple doses , an average of 1 year
Title
Pharmacokinetic (PK) Cmin
Description
PK parameters Cmin following single dose
Time Frame
after single dose , an average of 1 year
Title
Pharmacokinetic (PK) Tmax
Description
PK parameters Tmax following single dose
Time Frame
after single dose , an average of 1 year
Title
Pharmacokinetic (PK) AUC0-t
Description
PK parameters AUC0-t following single dose
Time Frame
after single dose , an average of 1 year
Title
Pharmacokinetic (PK) AUC0-∞
Description
PK parameters AUC0-∞ following single dose
Time Frame
after single dose , an average of 1 year
Title
Pharmacokinetic (PK) CL
Description
PK parameters CL following single dose
Time Frame
after single dose , an average of 1 year
Title
Pharmacokinetic (PK) Vd
Description
PK parameters Vd following single dose
Time Frame
after single dose , an average of 1 year
Title
Pharmacokinetic (PK) t1/2
Description
PK parameters t1/2 following single dose
Time Frame
after single dose , an average of 1 year
Title
Pharmacokinetic (PK) λz
Description
PK parameters λz following single dose
Time Frame
after single dose , an average of 1 year
Title
Objective response rate (ORR) (Phase I )
Description
To explore the preliminary effectiveness of IAE0972.
Time Frame
Baeline until disease progression or death, an average of 1 year
Title
Overall survival (OS) (Phase I )
Description
To explore the preliminary effectiveness of IAE0972.
Time Frame
Baeline until disease progression or death, an average of 1 year
Title
Disease control rate (DCR) (Phase I )
Description
To explore the preliminary effectiveness of IAE0972.
Time Frame
Baeline until disease progression or death, an average of 1 year
Title
To evaluate the Immunogenicity of IAE0972 in patients with advanced malignant solid tumors (Phase I )
Description
The frequency of anti-drug antibodies(ADA) against IAE0972
Time Frame
Before each administration of dose cycle,an average of 1 year
Title
Progression-free survival(PFS) in Phase II
Description
To explore the effectiveness of IAE0972.
Time Frame
Baeline until disease progression or death,assessed up to 36 months
Title
Overall survival (OS)in Phase II
Description
To explore the effectiveness of IAE0972.
Time Frame
Baeline until disease progression or death,assessed up to 36 months
Title
Disease control rate (DCR) in Phase II
Description
To explore the effectiveness of IAE0972.
Time Frame
Baeline until disease progression or death,assessed up to 36 months
Title
Immunogenicity of IAE0972 (Phase II )
Description
The frequency of anti-drug antibodies(ADA) against IAE0972
Time Frame
Before each administration of dose cycle,assessed up to 36 months
Title
Incidence of adverse event (AEs) and SAEs (Phase II)
Description
To investigate the safety characteristics
Time Frame
After last medication,assessed up to 36 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 1. Ability to provide informed consent and documentation of informed consent prior to initiation of any study-related tests or procedures that are not part of standard of care for the patient's disease. Patients must also be willing and able to comply with study procedures, including the acquisition of specified research specimens. 2. Male or female, of any race, aged between 18 years and 80 years; 3. With histologically or cytologically confirmed locally advanced or metastatic solid malignant tumors, either refractory to standard therapy or for which no effective therapy was available. 4. Measurable disease as determined by RECIST version 1.1 and documented by computed tomography (CT) and/or magnetic resonance imaging (MRI). 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Life expectancy ≥ 12 weeks. 7. Resolution of all chemotherapy or radiation-related toxicities to ≤ Grade 1 (with exception of ≤ Grade 2 alopecia, stable sensory neuropathy, or stable electrolyte disturbances that are managed by supplementation). 8. Acceptable laboratory parameters as follows: Platelet count (PLT) ≥ 90 × 109/L without transfusion within 2 weeks prior to the initiation of investigational product. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L in the absence of any growth factor support within 2 weeks prior to the initiation of investigational product. International normalized ratio of prothrombin time (INR) ≤ 1.5 × upper limit of normal (ULN), activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. Hemoglobin (HGB) ≥ 90 g/L. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN; for patients with hepatic metastases, ALT and AST ≤ 5.0 × ULN. Total bilirubin ≤ 1.5 × ULN, except patients with Gilbert's syndrome, who may enroll if the conjugated bilirubin is within normal limits. Serum creatinine < 1.5 × ULN, or estimated creatinine clearance ≥ 60 mL/min as measured or calculated using the Cockcroft-Gault formula. 9. Female patients of childbearing potential (not surgically sterilized and between menarche and 1- year postmenopause) must have a negative serum or urine pregnancy test performed within 7 days prior to the initiation of investigational product administration. Further, female patients of childbearing potential must agree to use highly effective contraceptive measures (include hormonal contraceptives, intrauterine device or system, vasectomy, or tubal ligation) from the time of consent through 3 months after discontinuation of investigational product administration. 10. Male patients with partners of childbearing potential must use barrier contraception. In addition, male patients should also have their partners use another method of contraception from the time of consent through 3 months after discontinuation of investigational product administration. Exclusion Criteria: 1. Known hypersensitivity (≥ Grade 3) to recombinant proteins or any excipient contained in the drug or vehicle formulation for IAE0972. 2. History of another malignancy or a concurrent malignancy. Exceptions include patients who have been disease free for two years, or successfully treated for non-melanoma skin cancer, localized prostate cancer (Gleason Score < 6) or carcinoma in situ, for example cervical cancer in situ, are eligible. 3. Treatment with any systemic anti-neoplastic therapy, radiation therapy or investigational therapy within 4 weeks prior to the initiation of investigational product administration, with the following exceptions: Nitrosourea or mitomycin C should be within 6 weeks prior to the initiation of investigational product administration. Oral fluoropyrimidines and small molecule targeted drugs should be within 2 weeks or 5 half-lives (whichever is later) prior to the initiation of investigational product administration. 4. History of trauma or major surgery within 4 weeks prior to the initiation of investigational product administration. 5. Treatment with corticosteroids (prednisone ≥ 10 mg per day or equivalent) or other immune suppressive drugs within the 14 days prior to the initiation of investigational product administration. Steroids for topical, ophthalmic, inhaled or nasal administration are allowed. 6. Treatment with immunomodulatory agents, including but not limited to thymosin, interleukin-2 and interferon within 14 days prior to the initiation of investigational product administration. 7. Vaccination with any live virus vaccine within 4 weeks prior to the initiation of investigational product administration. 8. History of prior allogeneic bone marrow, stem-cell or solid organ transplantation. 9. Active brain or leptomeningeal metastases. Patients with brain metastases are eligible if these have been treated and MRI or CT shows no evidence of progression for at least 8 weeks after treatment completion and within 4 weeks prior to the initiation of investigational product. Patients are not eligible if they required high doses of systemic corticosteroids that could result in immunosuppression (>10 mg/day prednisone equivalents) for at least 2 weeks prior to the initiation of investigational product. 10. Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of investigational product. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than one week prior to the initiation of investigational product. 11. Known history of hepatitis B or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction (PCR). 12. Known positive testing for human immunodeficiency virus (HIV) or history of acquired immune deficiency syndrome (AIDS). 13. Clinically significant pulmonary compromise, including a requirement for supplemental oxygen use to maintain adequate oxygenation. 14. History of clinically significant cardiovascular disease including but not limited to: Myocardial infarction or unstable angina within the 6 months prior to the initiation of investigational product. Stroke or transient ischemic attack within 6 months prior to the initiation of investigational product. Clinically significant cardiac arrhythmias, or a QTc prolongation to > 470 millisecond (ms) corrected by Fridericia's method based on a 12-lead electrocardiogram (ECG) in screening. Uncontrolled hypertension: systolic blood pressure (SBP) >180 mmHg, diastolic blood pressure (DBP) >100 mmHg. Congestive heart failure (New York Heart Association [NYHA] class III-IV). Pericarditis or clinically significant pericardial effusion. Myocarditis. Left ventricle ejection fraction (LVEF) < 50% by echocardiogram. 15. Any history of known or suspected autoimmune disease with the specific exceptions of vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic treatment (within the past 2 years), and patients with a history of autoimmune disease that are now clinically stable with replacement therapy and by laboratory testing. 16. History of ≥ grade 3 immune-related adverse events (irAE) or Grade 2 immune-associated myocarditis accompanied with immunotherapy. 17. Clinically uncontrolled effusion in the third space. 18. Known alcohol or drug dependence. 19. Dementia or altered mental status that would preclude understanding and rendering of informed consent. 20. The female patient who is pregnant or breastfeeding, or expecting to conceive, AND the male patient who is expecting to father children within the projected duration of the trial, starting with the screening visit through 90 days after the last dose of trial treatment. 21. Any issue that in the opinion of the investigator, would contraindicate the patient's participation in the study or confound the results of the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Minwei Manager
Phone
18068131816
Email
shenminwei@sunho-bio.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jin Li, M.D.
Organizational Affiliation
Shanghai East Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Yuping Sun, M.D.
Organizational Affiliation
Affilated Cancer Hospital of Shandong First Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Affilated Cancer Hospital of Shandong First Medical University
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250117
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yuping Sun, master
Phone
+86-0531-67627156
Email
13370582181@163.com
Facility Name
Shanghai East Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200120
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jin Li, master
Phone
+86-021-38804518
Email
lijin@csco.org.cn

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.

We'll reach out to this number within 24 hrs